- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 211/16 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
Patent holdings for IPC class C07D 211/16
Total number of patents in this class: 243
10-year publication summary
|
19
|
15
|
28
|
14
|
12
|
17
|
9
|
8
|
11
|
5
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Genzyme Corporation | 1263 |
6 |
| F. Hoffmann-La Roche AG | 7920 |
5 |
| Boehringer Ingelheim International GmbH | 4644 |
5 |
| Global Blood Therapeutics, Inc. | 183 |
5 |
| Incyte Holdings Corporation | 661 |
5 |
| Sanofi | 4068 |
5 |
| VALO Health, Inc. | 172 |
5 |
| Conopco, Inc. | 5039 |
4 |
| Incyte Corporation | 1025 |
4 |
| Marrone Bio Innovations, Inc. | 106 |
4 |
| Modernatx, Inc. | 1262 |
4 |
| Sagimet Biosciences Inc. | 26 |
4 |
| Excir Works Corp. | 31 |
4 |
| The Regents of the University of California | 19943 |
3 |
| AstraZeneca AB | 2900 |
3 |
| AstraZeneca UK Limited | 638 |
3 |
| Boehringer Ingelheim Pharma GmbH & Co. Kg | 553 |
3 |
| California Institute of Technology | 3975 |
3 |
| Commissariat à l'énergie atomique et aux energies alternatives | 10917 |
3 |
| Indiana University Research and Technology Corporation | 799 |
3 |
| Other owners | 162 |